title: Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood-brain barrier.
abstract: This report presents that Deferiprone, the only clinically used 3-hydroxypyridin-4-one (HPO), is able to penetrate the blood-brain barrier (BBB) in guinea pigs, whereas its glucosylated analogue is unable to do so. This finding is contrary to published information suggesting that the glucosylation of HPOs is a viable means of enhancing the brain uptake of this group of compounds.
authors.affiliation: Pharmaceutical Science Division, King's College London, London, UK.
authors.forename: Sourav
authors.initials: S
authors.lastname: Roy
authors.forename: Jane E
authors.initials: JE
authors.lastname: Preston
authors.forename: Robert C
authors.initials: RC
authors.lastname: Hider
authors.forename: Yong Min
authors.initials: YM
authors.lastname: Ma
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D000077543:Deferiprone; D006031:Glycosylation; D006168:Guinea Pigs; D007502:Iron Chelating Agents / Q000493:pharmacokinetics*; D008297:Male; D011728:Pyridones / Q000493:pharmacokinetics*; D051381:Rats; D014018:Tissue Distribution
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone